GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations

In June, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccines in all adults aged 75 and above.

The panel also recommended RSV immunization for adults aged 60-74 years who are at increased risk for severe RSV disease, meaning they have certain chronic medical conditions.

The recommendation is for adults who did not get an RSV vaccine last year. The RSV vaccine is not currently an annual vaccine.

ACIP postponed a vote on a recommendation for adults aged 50-59 years at increased risk for RSV-LRTD until additional data became available.

U.S. sales of RSV vaccines from GSK Plc (NYSE:GSK) and Pfizer Inc (NYSE:PFE) have declined after regulators narrowed the age group ...